Phagelux Overview
- Founded
- 2014
- Status
- Private
- Employees
- 5
- Latest Deal Type
- Series A
- Latest Deal Amount
- $10M
- Investors
- 2
Phagelux General Information
Description
Developer of bacteriophages designed to provide alternatives to antibiotics for multiple fields. The company offers anti-bacterial products across multiple fields utilizing various phage and phage-based technologies, enabling users solve the bacterial problem and provide treatments to various diseases.
Contact Information
Website
www.phagelux.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Primary Office
- 12th Floor, Huasheng Building
- 398 Hankou Road, Huangpu District
- Shanghai, 200001
- China
+86 021 0000 0000
Phagelux Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 09-Jun-2015 | $10M | 0000 | Completed | Startup | |
| 1. Seed Round | 06-Mar-2014 | Completed | Startup |
Phagelux Patents
Phagelux Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-9993532-B2 | Broad spectrum of streptococcus lyase and use thereof | Active | 13-Apr-2015 | 000000000 | |
| CA-2981996-A1 | Broad spectrum of streptococcus lyase and use thereof | Pending | 13-Apr-2015 | 000000000 | |
| US-20180104316-A1 | Broad spectrum of streptococcus lyase and use thereof | Granted | 13-Apr-2015 | 000000000 | |
| EP-3312275-A4 | Broad spectrum of streptococcus lyase and use thereof | Pending | 13-Apr-2015 | 000000000 | 0 |
| EP-3312275-A1 | Broad spectrum of streptococcus lyase and use thereof | Pending | 13-Apr-2015 | A61K38/51 |
Phagelux Executive Team (5)
Phagelux Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Edward Hu Ph.D | Self | Board Member | 000 0000 |
| Ge Li Ph.D | WuXi Healthcare Ventures | Board Member | 000 0000 |
| Mark Engel | Phagelux | Board Member, Founder & Chief Executive Officer | 000 0000 |
Phagelux Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialPhagelux Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Fosun Pharma | Corporation | Minority | 000 0000 | 000000 0 | |
| WuXi Healthcare Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |
Phagelux Investments & Acquisitions (4)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 00000 | 15-Mar-2021 | 00000 0000 | 00.000 | Biotechnology | |
| 00000000 0000 | 14-Oct-2015 | 0000000000 | Biotechnology | 0000000 0 | |
| 0000000000 | 20-Jul-2015 | 0000000000 | Multi-line Chemicals | 0000 0000 | |
| Iveria Technologies (Novel Delivery Systems) | 23-Dec-2014 | Merger/Acquisition | Drug Delivery |
Phagelux Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 0000000000 | Multi-line Chemicals | Sandy, UT | 0000 |